Introduction
Tofacitinib Extended Release Tablets 11mg (Tofacred-11 Tablets) are medicines given by doctors to treat diseases where the body’s defense system attacks its own healthy parts by mistake. These tablets help to lower swelling and pain in the body. They are taken once a day and release the medicine slowly all day.
Benefits of Tofacred-11 Tablets
-
Lowers joint pain and swelling
-
Helps you move better and more easily
-
Controls signs of autoimmune diseases
-
May reduce the need for other strong medicines like steroids
-
Easy to take just once a day
Features of Tofacred-11 Tablets
-
Long-acting tablet that works all day
-
Only needs to be taken once a day
-
Good for long-term treatment
-
Helps prevent sudden worsening of symptoms
Uses
-
Rheumatoid arthritis (pain and swelling in joints)
-
Psoriatic arthritis (joint pain with skin problems)
-
Ulcerative colitis (swelling in the large intestine)
-
Ankylosing spondylitis (pain and stiffness in the back and spine)
Usage
-
Take one tablet (11mg) once a day, at the same time every day.
-
Swallow the tablet whole with water. Do not crush, chew, or break it.
-
You can take it with or without food.
-
Follow the doctor’s advice exactly. Do not take more or less than told.
-
If you miss a dose, take it as soon as you remember. If it’s almost time for the next dose, skip the missed one. Do not take two tablets at once.
-
Go for regular checkups and blood tests as advised by your doctor to check for any side effects.
Advantages
-
Lowers swelling and joint pain well
-
Makes daily life easier for people with long-term diseases
-
Simple once-a-day tablet
-
Can work when other treatments don’t help
-
May reduce the need for steroids, which can cause more side effects
Disadvantages
-
May weaken the body’s defense system and cause infections
-
Can cause problems like headache, stomach pain, or higher cholesterol
-
Needs regular blood tests to check for safety
-
Not safe for some people with liver or kidney issues
-
May be costly without insurance




Reviews
There are no reviews yet.